Living Cell Technologies Limited
CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY
ASX ANNOUNCEMENT
LCT Appoints Scientific Advisors
23 September 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (LCT) has appointed three high-level scientific advisors to review and support its work
as NTCELL progresses towards commercialisation. The appointments are Professors Anne Young from Harvard, Roger Barker
from Cambridge and Richard Faull from Auckland. All are internationally recognised experts on the discovery of new
treatments for neurodegenerative diseases.
Professor Anne B Young, MD PhD, Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School, Boston,
United States, has over 40 years’ experience studying functional neuroanatomy. Her current research focuses on studies
of new therapeutic strategies for Parkinson’s and Huntington’s diseases.
Professor Roger Barker, MD PhD FRCP, Professor of Clinical Neurosciences and Deputy Director, John van Geest Centre for
Brain Repair, University of Cambridge, United Kingdom, has extensive experience in evaluating and developing new
therapies for Parkinson’s and Huntington’s diseases including cell therapies. His studies focus on disease heterogeneity
using cognitive testing, functional imaging and genetic biomarkers.
Professor Richard Faull, ONZM MBChB PhD DSc FRSNZ, Distinguished Professor of Anatomy and Director, Centre for Brain
Research, University of Auckland School of Medicine, has over 40 years’ research experience in anatomical studies of
human brain neuronal growth. He directs the Centre for Brain Research which carries out research and development
programs targeting neurodegenerative diseases such as Parkinson’s, Huntington’s, motor neuron and Alzheimer’s diseases.
Dr Ken Taylor, LCT chief executive says that input from these three internationally recognised experts will certainly
add huge value.
“Their oversight and expertise will enhance LCT’s ability to develop and market NTCELL® therapy for Parkinson’s patients
failing current therapy. Their expertise will also prove invaluable as we investigate the potential of our patented cell
therapy for other neurodegenerative disorders,” said Dr Taylor.
- Ends -